Verastem, Inc. Reports Data From Phase 1 Study Of VS-6063 (defactinib) In Japanese Patients
Published: Mar 06, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.
Help employers find you! Check out all the jobs and post your resume.